BrainsWay Ltd. (BWAY)
| Market Cap | 652.40M |
| Revenue (ttm) | 52.23M |
| Net Income (ttm) | 7.58M |
| Shares Out | 40.03M |
| EPS (ttm) | 0.18 |
| PE Ratio | 86.13 |
| Forward PE | 53.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,924 |
| Open | 16.35 |
| Previous Close | 16.50 |
| Day's Range | 16.00 - 16.36 |
| 52-Week Range | 4.30 - 16.69 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 13.25 (-17.85%) |
| Earnings Date | May 13, 2026 |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $13.25, which is a decrease of -17.85% from the latest price.
News
BrainsWay Ltd (BWAY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 68/100
BrainsWay Ltd (BWAY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 68/100
BrainsWay Ltd (BWAY) Shares Fall 3.0% -- GF Value Says Still Overvalued
BrainsWay Ltd (BWAY) Shares Fall 3.0% -- GF Value Says Still Overvalued
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administratio...
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
MEITAV INVESTMENT HOUSE LTD Acquires Significant Stake in BrainsWay Ltd
MEITAV INVESTMENT HOUSE LTD Acquires Significant Stake in BrainsWay Ltd
BrainsWay Ltd (BWAY) Stock Price Down 7.22% on Apr 6
BrainsWay Ltd (BWAY) Stock Price Down 7.22% on Apr 6
Zacks.com featured highlights include Cardinal Infrastructure, BrainsWay and Century Aluminum
Century Aluminum surges on strong demand and pricing power, while select stocks like Cardinal Infrastructure show resilience amid a weak broader market.
Here's Why Momentum in Brainsway (BWAY) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price...
BrainsWay (BWAY) Invests $1M in Axis Integrated Mental Health Venture
BrainsWay (BWAY) Invests $1M in Axis Integrated Mental Health Venture
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner...
Micron To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . HC Wainwr...
BrainsWay Ltd (BRSYF) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advances
BrainsWay Ltd (BRSYF) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advances
BrainsWay (BWAY) Soars 10% on Strong Q4 Earnings and Optimistic 2026 Outlook
BrainsWay (BWAY) Soars 10% on Strong Q4 Earnings and Optimistic 2026 Outlook
Q4 2025 Brainsway Ltd Earnings Call Transcript
Q4 2025 Brainsway Ltd Earnings Call Transcript
BrainsWay Reports Q4 Earnings: Revenue Beat, Guidance Below Estimates
BrainsWay Ltd. (NASDAQ: BWAY) reported fourth-quarter financial results on Wednesday ahead of the market open.
BrainsWay Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 revenue grew 27% year-over-year, exceeding guidance, with 10 straight profitable quarters and expanding margins. Recurring revenue and strategic investments are driving growth, while new FDA clearances and payer coverage support future expansion.
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...
Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE: CXM) is estimated to report quarterly earnings at $0.08 per share on revenue of $216.94 million. • Smith Douglas Homes (NYSE: SDHC) is projected...
Uncovering Potential: BrainsWay's Earnings Preview
BrainsWay (NASDAQ: BWAY) is gearing up to announce its quarterly earnings on Wednesday, 2026-03-11. Here's a quick overview of what investors should know before the release. Analysts are estimating t...
Earnings To Watch: BrainsWay Ltd (BWAY) Reports Q4 2025 Result
Earnings To Watch: BrainsWay Ltd (BWAY) Reports Q4 2025 Result
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
BrainsWay (BWAY) Announces Breakthrough in Depression Treatment
BrainsWay (BWAY) Announces Breakthrough in Depression Treatment
Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70...
Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression ...
BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technol...